UPL Ltd
UPLUPL Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +114.5% against a −17.3% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (26 weeks in) while the P/E sits at the 60th percentile of its own 11-year range. Underneath, the last four quarters read mixed, and 346% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
UPL Ltd trades at ₹573, in a downtrend and 26 weeks into that stage. That is −9.0% against its own 200-day average. It sits at 4% of a 52-week range of ₹563 to ₹805. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (18 weeks and counting).
Today the stock is in a downtrend — week 26 of stage 4, confirmed. At ₹573 it trades −9.0% versus its 200-day average and sits at 4% of its 52-week range (₹563–₹805).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +104% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (18 weeks and counting; last ahead the week of 2026-06-05) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
UPL Ltd trades at 24.5× P/E, mid-range by its own standards (60th percentile). Its long-run median P/E is 21.3×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 24.5× is mid-range by its own standards (60th percentile), against a long-run median of 21.3× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +114.5% against a −17.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −4.7%/yr price move, ~−8.6%/yr came from earnings growth and ~+3.9 pp from the multiple (expanding); over 10y, of the +3.1%/yr price move, ~+5.3%/yr came from earnings growth and ~−2.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, UPL Ltd was paying for profit growth of about 15.0% a year. Profit itself has compounded 8.8% a year over the past 10 years. Today the market pays 24.5× P/E, the 60th percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
UPL Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 10.9% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.2% | −1.1% | +6.0% | +13.9% |
| Profit | +170.7% | −20.5% | −8.7% | +8.8% |
| EPS | +114.5% | −18.6% | −7.4% | +5.8% |
| Share price | −17.3% | −0.5% | −4.7% | +3.1% |
4-Factor Sector Score
42.2/100 — rank 16 of 24 in Pesticides/Agrochemicals · 91% evidence confidence
UPL Ltd scores 42.2 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.1 + 8.3 + 12.2 + 4.6 = 42.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
UPL Ltd reported ₹10,181 Cr of revenue in the Jun 26 quarter, +10.5% year on year. That is the 9th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.9% a year. The last full year, FY26, came in at ₹51,839 Cr. The last four reported quarters add to ₹52,804 Cr.
FY26 revenue came in at ₹51,839 Cr (+11.2% on the year), capping 10 years at 13.9% compound. The latest quarter (Jun 26) printed ₹10,181 Cr, +10.5% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.3% growth against the decade's 13.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +12.9% over the last 4 quarters against +10.6%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
UPL Ltd's operating margin is 13.0% in the Jun 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 22.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–22.0%.
🚨 Why the margin moved: operating margin went −1.7 pp year on year while gross margin went +2.9 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
UPL Ltd posted a net loss of ₹73.0 Cr in the Jun 26 quarter. Full-year FY26 profit was ₹2,220 Cr. The 10-year compound rate is 8.8%. That loss is 0.7% of the quarter's revenue. The same quarter a year earlier lost ₹176 Cr. 7 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹−73.0 Cr, null year on year. On the full year, FY26 printed ₹2,220 Cr (+170.7%), and the 10-year compound rate is 8.8%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 346% of UPL Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹7,855 Cr of operating cash against ₹2,220 Cr of profit. After ₹6,914 Cr of capital spending, ₹941 Cr was left as free cash.
FY26: operating cash of ₹7,855 Cr against reported profit of ₹2,220 Cr, leaving free cash of ₹941 Cr after ₹6,914 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 346% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 346%: the cash cycle stretched 84 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
UPL Ltd's cash conversion cycle runs 135 days in FY26, up from 51 days in FY21. Capital spending ran ₹12,526 Cr over the last 3 years. At FY26 sales of ₹51,839 Cr each day of that cycle holds about ₹142 Cr, so roughly ₹19,173 Cr sits inside the business at any moment.
FY26: debtors at 126 days, inventory at 179 days — roughly 5.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 135 days, looser than FY21's 51.
The full loop: cash goes out to suppliers and production on day 0; stock waits 179 days to sell; customers pay about 126 days after that; and suppliers themselves are paid at 169 days — netting out to the 135-day cycle.
In money terms: at FY26 sales of ₹51,839 Cr, each day of the cycle holds about ₹142 Cr — so the 135-day loop keeps roughly ₹19,173 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹12,526 Cr over the last 3 fiscal years against ₹8,757 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹3,147 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
UPL Ltd earns a ROCE of 10% in FY26. That is up from a trough of 3% in FY24. Return on invested capital clears the cost of that capital by −4.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.3% net margin on 0.56× asset turns.
FY26 ROCE is 10%, recovered from a FY24 trough of 3% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 4.3% net margin × 0.56× asset turns × 2.68× balance-sheet leverage ≈ 6.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 7.9% − 12.0% = a −4.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
UPL Ltd carries total debt of ₹23,576 Cr against shareholder equity of ₹41,269 Cr as of Mar 26, a debt-to-equity of 0.57. On the annual view that ratio went from 0.91 in FY22 to 0.57 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹23,576 Cr against shareholder equity of ₹41,269 Cr — a debt-to-equity of 0.57. On the annual view, debt-to-equity went from 0.91 (FY22) to 0.57 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 8.2 points of UPL Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 42.4% of the company. Domestic institutions moved −3.3 points over the same window, to 14.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +8.2 points over 8 quarters to 42.4%; Domestic institutions: −3.3 points over 8 quarters to 14.3%; Promoters: +1.0 points over 8 quarters to 33.5%.
Why the register moved: rotation — foreign institutions +8.2 points against domestic institutions −3.3 points over 8 quarters, with promoters +1.0 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
UPL Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bayer CropScience LtdBAYERCROP | 71.8/100Favorable setup94% evidence | BASING | 22.9/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 100% evidence | 21.2/25 ROCE 29.1% · OPM 20% 100% evidence | 14.7/20 P/E 24.4× · PEG 1.28 100% evidence | 13.0/20 RS sector 9.4% · RS bench -11% · 1Y -21.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.9 + 21.2 + 14.7 + 13 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Titan Biotech Ltd524717 | 68.9/100Favorable setup82% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 2 pp 95% evidence | 20.1/25 ROCE 22.8% · OPM 21% 76% evidence | 5.7/20 P/E 53.3× · PEG — 50% evidence | 14.0/20 RS sector 35.7% · RS bench 34.4% · 1Y 213.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.1 + 5.7 + 14 = 68.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Sharda Cropchem LtdSHARDACROP | 64.7/100Mixed-positive evidence100% evidence | BASING | 24.2/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 100% evidence | 19.6/25 ROCE 30.2% · OPM 17% 100% evidence | 18.7/20 P/E 11× · PEG 0.26 100% evidence | 2.2/20 RS sector -14.6% · RS bench -15.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 19.6 + 18.7 + 2.2 = 64.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.6% and the one-year return is -16.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4Dharmaj Crop Guard LtdDHARMAJ | 63.2/100Mixed-positive evidence74% evidence | BASING | 21.1/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.9/25 ROCE 16.8% · OPM 15% 95% evidence | 10.9/20 P/E 15.1× · PEG — 15% evidence | 15.3/20 RS sector 5% · RS bench 4.5% · 1Y -27.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 15.9 + 10.9 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 60.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 23.4/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 17.9/25 ROCE 18.6% · OPM 12% 95% evidence | 11.6/20 P/E 19.5× · PEG — 50% evidence | 7.6/20 RS sector -6.2% · RS bench -5.8% · 1Y -4.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.4 + 17.9 + 11.6 + 7.6 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.9/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence | 14.8/25 ROCE 19.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 21.3 + 14.8 + 10.8 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7India Pesticides LtdIPL | 52.9/100Mixed-positive evidence81% evidence | BASING | 20.1/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.7/25 ROCE 16.6% · OPM 14% 95% evidence | 14.1/20 P/E 14.3× · PEG — 50% evidence | 5.0/20 RS sector -11.9% · RS bench -17.5% · 1Y -35.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 20.1 + 13.7 + 14.1 + 5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.9/100Mixed-positive evidence100% evidence | ASLEEP | 29.1/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence | 7.0/25 ROCE 4.5% · OPM 16% 100% evidence | 1.6/20 P/E 122× · PEG 8.06 100% evidence | 14.2/20 RS sector 9.1% · RS bench 7.6% · 1Y -4.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 7 + 1.6 + 14.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Rallis India LtdRALLIS | 50.9/100Mixed-positive evidence94% evidence | BASING | 20.4/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 100% evidence | 10.6/25 ROCE 14.1% · OPM 18% 100% evidence | 11.5/20 P/E 17.2× · PEG 2.15 100% evidence | 8.4/20 RS sector -1.8% · RS bench -19% · 1Y -43.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 10.6 + 11.5 + 8.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Astec Lifesciences LtdASTEC | 50.9/100Mixed-positive evidence69% evidence | BASING | 23.9/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 3.2/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.8/20 RS sector 5.1% · RS bench 3.6% · 1Y -17.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 3.2 + 10 + 13.8 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Jubilant Ingrevia LtdJUBLINGREA | 50.5/100Mixed-positive evidence93% evidence | TURNING | 19.0/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.4% · OPM 15% 100% evidence | 6.1/20 P/E 33× · PEG 2.41 65% evidence | 14.8/20 RS sector 0.7% · RS bench -0.6% · 1Y -8.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 10.6 + 6.1 + 14.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Sumitomo Chemical India LtdSUMICHEM | 46.2/100Mixed-negative evidence94% evidence | FADING | 12.6/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 5.5/20 P/E 41.6× · PEG 4 100% evidence | 9.1/20 RS sector -8.2% · RS bench 3.2% · 1Y -16.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 5.5 + 9.1 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13NACL Industries LtdNACLIND | 45.9/100Mixed-negative evidence100% evidence | ASLEEP | 29.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 3.9/25 ROCE 8.1% · OPM 11% 100% evidence | 3.7/20 P/E 142× · PEG 2.02 100% evidence | 9.2/20 RS sector -4.3% · RS bench -5.8% · 1Y -35%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 3.9 + 3.7 + 9.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Meghmani Organics LtdMOL | 45.8/100Mixed-negative evidence74% evidence | BREAKING OUT | 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 7.8/25 ROCE 6.7% · OPM 18% 95% evidence | 9.4/20 P/E 24.8× · PEG — 15% evidence | 7.8/20 RS sector -33.7% · RS bench 7.6% · 1Y -22%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 7.8 + 9.4 + 7.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Excel Industries LtdEXCELINDUS | 42.8/100Mixed-negative evidence74% evidence | TURNING | 12.4/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 6.2% · OPM 14% 95% evidence | 10.4/20 P/E 17.3× · PEG — 15% evidence | 9.7/20 RS sector -4.6% · RS bench 1.7% · 1Y -15.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 10.3 + 10.4 + 9.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16UPL Ltdthis pageUPL | 42.2/100Mixed-negative evidence91% evidence | BASING | 17.1/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence | 8.3/25 ROCE 10.1% · OPM 13% 100% evidence | 12.2/20 P/E 24.5× · PEG 0.5 100% evidence | 4.6/20 RS sector -11.6% · RS bench -12.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.3 + 12.2 + 4.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Rasayan LtdBHARATRAS | 41.9/100Mixed-negative evidence87% evidence | ASLEEP | 10.8/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence | 13.6/25 ROCE 16% · OPM 15% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 3.1/20 RS sector -32.8% · RS bench -34% · 1Y -53.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 13.6 + 14.4 + 3.1 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Epigral LtdEPIGRAL | 41.2/100Mixed-negative evidence94% evidence | TURNING | 7.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.5/25 ROCE 15.5% · OPM 25% 100% evidence | 14.4/20 P/E 18× · PEG 0.43 100% evidence | 4.8/20 RS sector -32.9% · RS bench -6.6% · 1Y -35.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 7.5 + 14.5 + 14.4 + 4.8 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Dhanuka Agritech LtdDHANUKA | 40.8/100Mixed-negative evidence100% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence | 16.2/25 ROCE 23.8% · OPM 12% 100% evidence | 11.4/20 P/E 16.3× · PEG 1.72 100% evidence | 6.6/20 RS sector -11% · RS bench -12.4% · 1Y -38.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.6 + 16.2 + 11.4 + 6.6 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Best Agrolife LtdBESTAGRO | 40.0/100Mixed-negative evidence87% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.1/25 ROCE 5.2% · OPM 20% 95% evidence | 8.8/20 P/E 22.8× · PEG — 50% evidence | 14.2/20 RS sector -0.4% · RS bench -1.8% · 1Y -27.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 9.1 + 8.8 + 14.2 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Insecticides India LtdINSECTICID | 37.6/100Mixed-negative evidence87% evidence | BASING | 10.7/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence | 10.8/25 ROCE 15.8% · OPM 11% 95% evidence | 11.5/20 P/E 14.2× · PEG — 50% evidence | 4.6/20 RS sector -6.7% · RS bench -8% · 1Y -23.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.8 + 11.5 + 4.6 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22P I Industries LtdPIIND | 35.3/100Mixed-negative evidence94% evidence | BASING | 4.7/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence | 13.8/25 ROCE 15% · OPM 22% 100% evidence | 9.5/20 P/E 31.7× · PEG 1.71 100% evidence | 7.3/20 RS sector -3.4% · RS bench -25.1% · 1Y -38.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.7 + 13.8 + 9.5 + 7.3 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Heranba Industries LtdHERANBA | 28.0/100Adverse evidence77% evidence | BASING | 8.9/35 Revenue -2.6% · PAT -80% · OPM change 5.9 pp 95% evidence | 2.8/25 ROCE -1.7% · OPM 12.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -19% · RS bench -20.3% · 1Y -48.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 2.8 + 10 + 6.3 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24GSP Crop Science LtdGSPCROP | 47.7/100Thin evidence · provisional38% evidence | BREAKING OUT | 14.2/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 13.6/25 ROCE 18.9% · OPM 11% 76% evidence | 9.9/20 P/E 21× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 9 weeks ahead 0% evidence |
| Exact sum: 14.2 + 13.6 + 9.9 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is UPL Ltd's share price today?
UPL Ltd trades at ₹573, −17.3% over the past year. The company is valued at ₹48,352 Cr. The stock sits at 4% of its 52-week range of ₹563–₹805, −9.0% versus its 200-day average. On the tape, the price is in a downtrend, 26 weeks in. — as of 11 September 2026.
What were UPL Ltd's latest quarterly results?
UPL Ltd reported revenue of ₹10,181 Cr and a net loss of ₹73.0 Cr for the Jun 26 quarter. The operating margin was 13.0%, 2.0 pp lower than a year earlier. — as of 11 September 2026.
What is UPL Ltd's revenue?
UPL Ltd reported revenue of ₹10,181 Cr in the Jun 26 quarter, +10.5% year on year. For the full FY26 fiscal year, revenue was ₹51,839 Cr (+11.2%). Over the last 10 years revenue compounded at 13.9% a year. — as of 11 September 2026.
What is UPL Ltd's profit?
UPL Ltd earned ₹−73.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹2,220 Cr. The operating margin ran 13.0% in the latest quarter. — as of 11 September 2026.
What is UPL Ltd's market cap?
UPL Ltd's market capitalisation is ₹48,352 Cr at a share price of ₹573. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is UPL Ltd's P/E ratio?
UPL Ltd trades at a P/E of 24.5×, at the 60th percentile of its own 11-year range, against a long-run median of 21.3×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does UPL Ltd pay a dividend?
Yes — UPL Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in 12 of its last 13 reported fiscal years. One of those years shows a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is UPL Ltd overvalued?
On its own history, UPL Ltd looks mid-range: its P/E of 24.5× sits at the 60th percentile of its 11-year range (long-run median 21.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
How is UPL Ltd performing?
UPL Ltd is in a downtrend, 26 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 18 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is UPL Ltd in?
Mixed — no clean majority across the growth curves, ROCE lifting at 10.9% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +12.9% latest, eps growth +69.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is UPL Ltd in an uptrend?
No — the price is in a downtrend (week 26 of stage 4), trading −9.0% versus its 200-day average and at 4% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is UPL Ltd beating the market?
Not lately — on a trailing-13-week view UPL Ltd is currently behind the NIFTY 500 (18 weeks and counting; last ahead the week of 2026-06-05), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +104% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will UPL Ltd's share price go up?
This page publishes no price forecast for UPL Ltd. What it measures instead: the share price is ₹573, the price is in a downtrend 26 weeks in. Its P/E of 24.5× sits at the 60th percentile of its own 11-year range. Direction is not something this site claims to know. — as of 11 September 2026.
Who owns UPL Ltd?
Promoters hold 33.5% of UPL Ltd, foreign institutions 42.4%, domestic institutions 14.3% and the public 9.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 8.2 points over 8 quarters. — as of 11 September 2026.
Does UPL Ltd have too much debt?
It is moderate — UPL Ltd's debt-to-equity is 0.68, and operating profit covers the interest bill 3×. FY26 borrowings were ₹23,576 Cr against equity of ₹34,696 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is UPL Ltd's capex?
UPL Ltd spent ₹12,526 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹6,914 Cr, with ₹3,147 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is UPL Ltd's cash flow?
UPL Ltd generated ₹7,855 Cr of operating cash flow in FY26 and ₹941 Cr of free cash flow after ₹6,914 Cr of capital spending. Reported profit that year was ₹2,220 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is UPL Ltd's profit real cash?
Yes — over the last 3 fiscal years, 346% of UPL Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹7,855 Cr against reported profit of ₹2,220 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is UPL Ltd in its business cycle?
UPL Ltd's FY26 operating margin was 18.0%, against a 13-year band of 10.0%–22.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does UPL Ltd's price assume?
At its price on 13 June 2026, UPL Ltd was priced for profit growth of about 15.0% a year. Profit itself has compounded 8.8% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the UPL Ltd story?
The sharpest disagreement: annual EPS moved +114.5% against a −17.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is UPL Ltd a stock worth studying right now?
This is not investment advice. The machine read: UPL Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!